CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)

NCT ID: NCT03317028

Last Updated: 2020-06-09

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 201 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-10-10
• Study Completion Date: 2020-04-21

Brief Summary

The objective of the study is to compare the efficacy and safety of 3 doses CS02 Tablet in combination with a stable dose of metformin monotherapy against CS02 PTM (placebo) Tablet in combination with a stable dose of metformin monotherapy over a 12 weeks treatment period in subjects with type 2 diabetes mellitus with inadequate glycemic control on metformin alone.

Conditions

T2DM With Inadequate Glycemic Control

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

high dose of CS02

Subjects will receive 450mg of CS02 combined with a stable dose of metformin monotherapy.

Group Type: EXPERIMENTAL

CS02 tablet and placebo tablet

Intervention Type: DRUG

Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.

middle dose of CS02

Subjects will receive 300mg of CS02 combined with a stable dose of metformin monotherapy.

Group Type: EXPERIMENTAL

CS02 tablet and placebo tablet

Intervention Type: DRUG

Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.

low dose of CS02

Subjects will receive 150mg of CS02 combined with a stable dose of metformin monotherapy.

Group Type: EXPERIMENTAL

CS02 tablet and placebo tablet

Intervention Type: DRUG

Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.

placebo control

Subjects will receive placebo combined with a stable dose of metformin monotherapy.

Group Type: PLACEBO_COMPARATOR

CS02 tablet and placebo tablet

Intervention Type: DRUG

Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.

Interventions

CS02 tablet and placebo tablet

Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subjects with diagnosis of type 2 diabetes mellitus at least 12 weeks prior to Visit 1;

2. Outpatient, either male or female, aged 20 years or older from Taiwan and aged 18 years or older from united States; all subjects are ≤75 years old;

3. Subjects with a stable diet and exercise program for ≧8 weeks prior to Visit 1;

4. Subjects with HbA1c value ≧7.0% and ≦10.0% at Visit 1;

5. Subjects with a stable dose of metformin monotherapy of ≥1500 mg/day at least 12 weeks before randomization (Visit 2);

6. Body mass index (BMI) between 20.0 and 45.0 kg/m2at Visit 1;

7. Subjects have adequate liver function, defined as serum total bilirubin≤1.5 times the upper limit of normal (uLN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤3 times uLN at Visit 1;

8. Subjects have estimated glomerular filtration rate (e-GFR)* values of≧ 45ml/min/1.73m2 at Visit1;

9. Female subjects of childbearing potential， defined as women≤ 55 years old or history of amenorrhea ≤ 12 months prior to the study entry or not surgically sterile, must have a negative pregnancy test at Visit 1 and agree to use a highly effective contraceptive method during the study period;

10. Willing to provide a written informed consent form;

11. Willingness and ability to comply with treatment plans, scheduled visits, required laboratory tests, and other study procedures;

Exclusion Criteria

1. Subjects with type 1 diabetes mellitus, secondary diabetes mellitus, or gestational diabetes;

2. Subjects with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma at Visit 1 or Visit 2;

3. Subjects with hypotension (average systolic pressure < 90 mm Hg*) at Visit 1 or Visit 2;

4. Subjects with cardiogenic shock within 8 weeks prior to Visit 1;

5. Subjects with sick sinus syndrome, second- or third-degree atrioventricular block (AV block);

6. Subjects with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., Wolff-Parkinson-White, Lown-Ganong-Levine syndromes);

7. Subjects with recurrence or history of transient ischemic attack or coronary artery bypass surgery;

8. Subjects with history of cerebrovascular attack, myocardial infarction, serious cardiac disease (New York Heart Association NYHA Class III to IV), left ventricular ejection fraction≦40% within 12 weeks prior to Visit 1, or those with cardiovascular disease or cerebrovascular disease that may affect the administration of IP tablets (CS02) or its safety assessment in the opinion of the investigator or sub-investigator;

9. Female subjects who are nursing or pregnant during the study period;

10. Subjects are on a weight loss program and not in the maintenance phase or have started a weight loss medication including but not limited to Orlistat, Phentermine, Osymia, or Belviq or have undergone bariatric surgery within 8 weeks prior to Visit 1 or any type of surgery planned during the study;

11. Subjects with a clinically severe gastrointestinal disorder including diabetic gastroparesis; irritable bowel disease; recurrent episodes of nausea, vomiting, diarrhea and abdominal pain within 12 weeks prior to Visit 1;

12. Subjects have a history or current of substance or alcohol abuse;

13. Subjects have uncontrolled psychiatric disorder(s);

14. Subjects are less than 5 years free of malignancy (except for cured basal cell carcinoma of skin and cured carcinoma in situ of the uterine cervix);

15. Subjects have participated in another clinical trial within the last 12 weeks prior to Visit 1;

16. Subjects who are considered unreliable as to medication compliance or adherence to scheduled appointments, or inappropriate for inclusion per investigators, judgments;

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Center Laboratories, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Applied Research Center of Arkansas, Inc.

Little Rock, Arkansas, United States

Clinical Research of South Florida

Coral Gables, Florida, United States

The Community Research of South Florida

Hialeah, Florida, United States

Kaohsiung Veterans General Hospital

Kaohsiung City, , Taiwan

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, , Taiwan

Chung Shan Medical University Hospital

Taichung, , Taiwan

China Medical University Hospital

Taichung, , Taiwan

Taichung Veterans General Hospital

Taichung, , Taiwan

Chi-Mei Medical Center

Tainan City, , Taiwan

National Taiwan University Hospital

Taipei, , Taiwan

Taipei Veterans general Hospital

Taipei, , Taiwan

Tri-Service General Hospital

Taipei, , Taiwan

Chang Gung Memorial Hospital_Linkou

Taoyuan District, , Taiwan

Countries

United States; Taiwan

References

Wang CY, Huang KC, Lu CW, Chu CH, Huang CN, Chen HS, Lee IT, Chen JF, Chen CC, Chen CS, Hsieh CH, Tien KJ, Chien HY, Huang YY, Hsu JP, Shane GT, Chang AC, Wu YC, Sheu WH. A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes. J Clin Endocrinol Metab. 2022 Sep 28;107(10):e4063-e4071. doi: 10.1210/clinem/dgac436.

Reference Type: DERIVED

PMID: 35917580 (View on PubMed)

Other Identifiers

CS02-001

Identifier Type: -

Identifier Source: org_study_id

NCT03308695

Identifier Type: -

Identifier Source: nct_alias